Short summary

to analyze individual dosing of a-CD20 during COVID-19

Rationale

a-CD20 is only used with one dosing and one interval but other studies have suggested similar efficacy when using extended dosing interval (EID)

Description of the cohort

Patient with MS that had EID og regular interval during the COVID-19 pandemic

Data and biological material

serum, plasma and flowcytbmetry results

Collaborating researchers and departments

DMSG, Rigshospitalet Glostrup

• Finn Sellbjerg
• Stephan Brammow

Hillerød Hospital

• Kamilla Østergaard

Viborg Hospital

• Jonas Munksgaard

Aarhus Hospital

• Morten Stilund

Odense Hospital

• Zsolt Illes

Klinisk Immunologisk Afdeling, Odense

• Christine Nielsson
• Christian Nielsen

UCSF

• Joseph Sabatino

Publications associated with the project

Novak F, Nilsson AC, Nielsen C, Holm DK, Ostergaard K, Bystrup A, et al. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2021;56

Novak F, Ostergaard K, Berg JM, Kristensen CH, Illes Z, Sellebjerg F, et al. Extended dosage interval of B-cell therapy in multiple sclerosis. Multiple Sclerosis Journal. 2021;27(2_SUPPL):767-.

Bajwa HM, Novak F, Nilsson AC, Nielsen C, Holm DK, Ostergaard K, et al. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 2022;60.